Skip to main content

Mayzent FDA Approval History

Last updated by Judith Stewart, BPharm on April 10, 2019.

FDA Approved: Yes (First approved March 26, 2019)
Brand name: Mayzent
Generic name: siponimod
Dosage form: Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: Multiple Sclerosis

Mayzent (siponimod) is a sphingosine-1-phosphate receptor modulator for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.